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COMMENTARY
Combining malaria vaccination 
with chemoprevention: a promising new 
approach to malaria control
Brian Greenwood1* , Matthew Cairns1, Mike Chaponda2, R. Matthew Chico1, Alassane Dicko3, 
Jean‑Bosco Ouedraogo4, Kamija S. Phiri5, Feiko O. ter Kuile6 and Daniel Chandramohan1 
Abstract 
Malaria control has stalled in a number of African countries and novel approaches to malaria control are needed for 
these areas. The encouraging results of a recent trial conducted in young children in Burkina Faso and Mali in which a 
combination of the RTS,S/AS01E malaria vaccine and seasonal malaria chemoprevention led to a substantial reduction 
in clinical cases of malaria, severe malaria, and malaria deaths compared with the administration of either intervention 
given alone suggests that there may be other epidemiological/clinical situations in which a combination of malaria 
vaccination and chemoprevention could be beneficial. Some of these potential opportunities are considered in this 
paper. These include combining vaccination with intermittent preventive treatment of malaria in infants, with inter‑
mittent preventive treatment of malaria in pregnancy (through vaccination of women of child‑bearing age before or 
during pregnancy), or with post‑discharge malaria chemoprevention in the management of children recently admit‑
ted to hospital with severe anaemia. Other potential uses of the combination are prevention of malaria in children at 
particular risk from the adverse effects of clinical malaria, such as those with sickle cell disease, and during the final 
stages of a malaria elimination programme when vaccination could be combined with repeated rounds of mass drug 
administration. The combination of a pre‑erythrocytic stage malaria vaccine with an effective chemopreventive regi‑
men could make a valuable contribution to malaria control and elimination in a variety of clinical or epidemiological 
situations, and the potential of this approach to malaria control needs to be explored.
Keywords: Seasonal malaria vaccination, Seasonal malaria chemoprevention, Intermittent preventive treatment 
of malaria in infants, Intermittent preventive treatment of malaria in pregnancy, Post hospital discharge 
chemoprevention, Sickle cell disease, Malaria elimination
© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which 
permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the 
original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or 
other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line 
to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory 
regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this 
licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/. The Creative Commons Public Domain Dedication waiver (http:// creat iveco 
mmons. org/ publi cdoma in/ zero/1. 0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
Substantial progress has been made in the control 
of malaria in the past 2  decades, with the incidence 
of malaria deaths reduced by over a half and malaria 
cases by nearly a third. In the same period, ten 
countries have been certified by The World Health 
Organization (WHO) as having eliminated malaria 
[1]. However, progress has stalled in recent years in 
many countries in sub-Saharan Africa, where malaria 
remains a major cause of death and serious illness in 
young children. This levelling off in progress has led 
the WHO to establish a ‘High burden-High Impact’ 
programme [2] targeted at India and the ten African 
countries with the highest burden of malaria. Novel 
approaches to malaria control are required in these 
countries. The encouraging results of a recent trial 
conducted in young children in Burkina Faso and Mali, 
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that a potential new approach to malaria control in 
countries where this is proving challenging is combin-
ing vaccination with a pre-erythrocytic malaria vac-
cine with chemoprevention [3]. This paper reviews 
some of the situations in which this might be a useful 
new approach to malaria control.
The rationale for combining malaria vaccination 
and chemoprevention
Three of the most advanced Plasmodium falciparum 
malaria vaccines (RTS,S/AS01E, PfSPZ and R21) are 
pre-erythrocytic vaccines, which induce an immune 
response directed at the sporozoite or liver stage of the 
parasite’s life-cycle. The humoral and cellular immune 
responses induced by these vaccines are highly effective 
at preventing in the short term the establishment or 
full development of liver schizonts, but the persistence 
and rupture of a single schizont are sufficient to estab-
lish a blood-stage infection that could result in a severe 
episode of malaria or even death. An approach that is 
currently being explored to overcome this challenge is 
combining a pre-erythrocytic stage vaccine with one 
that induces an immune response against blood stages 
of the parasite, thus aborting the infection [4]. How-
ever, the development of an effective blood-stage vac-
cine has proved challenging because of polymorphism 
in the key blood-stage antigens, such as AMA1, that 
have been the initial targets for blood-stage vaccine 
development [5]. A vaccine based on the conserved 
Rh5 antigen may overcome this problem [6], but this 
candidate vaccine is still only at an early stage of clini-
cal development. In contrast to the immune response 
induced by the first generation of blood-stage vaccine 
candidates, antimalarial drugs to which the parasite 
is sensitive can rapidly kill any blood-stage parasites 
regardless of the parasite strain and provide protection 
for several weeks dependent upon the anti-malarial 
used. Therefore, combining vaccination and chemopre-
vention in an appropriately targeted way could play an 
important role in the control of malaria where this is 
currently proving difficult.
Chemoprevention at a population level is used for 
malaria control in highly endemic areas in various 
ways, including intermittent preventive treatment 
of malaria in pregnancy with sulfadoxine-pyrimeth-
amine (IPTp-SP), intermittent preventive treatment of 
malaria in infants with SP (IPTi-SP), seasonal malaria 
chemoprevention (SMC) and mass drug administra-
tion (MDA). However, the potential benefit of combin-
ing vaccination and malaria chemoprevention with an 
effective schizonticidal drug or drug combination has 
only recently been explored [7–9].
Combining RTS,S/AS01E vaccination with seasonal 
malaria chemoprevention
The first phase of a trial undertaken in young children in 
Burkina Faso and Mali to investigate the impact of com-
bining vaccination with the RTS,S/AS01E malaria vac-
cine with SMC has recently been completed [7, 8]. In 
this study, conducted in areas of highly seasonal malaria 
transmission, 5920 children were enrolled at the age 
of 5–17  months and allocated to one of three groups. 
Children in one group received four, monthly courses of 
SMC with sulfadoxine-pyrimethamine plus amodiaquine 
(SP  +  AQ) each year during the malaria transmission 
season (the standard of care in both countries) plus 
control non-malarial vaccines (rabies and hepatitis A), 
those in a second group received RTS,S/AS01E plus an 
SMC placebo, and those in a third group received both 
RTS,S/AS01E and SMC. RTS,S/AS01E was administered 
in three, monthly priming doses prior to the 2017 malaria 
transmission season, and then a single booster dose was 
given shortly before the start of the malaria transmis-
sion season during each of the following two years (2018 
and 2019). All children were provided with an insecti-
cide-treated bednet at the start of the trial. The primary 
trial endpoint was the incidence of clinical attacks of 
malaria; predefined secondary endpoints included hos-
pital admissions with malaria and death from malaria 
[7]. During three years of follow-up, RTS,S/AS01E alone 
was non-inferior to SMC in preventing malaria and the 
combination of the two interventions led to a substan-
tial reduction in the incidence of uncomplicated cases 
of malaria, hospital admissions with malaria and deaths 
from malaria over the level of protection obtained with 
either intervention given alone. A high level of protection 
was observed in the children in the group who received 
both interventions during the second and third years of 
the trial when children received only a single booster 
dose of RTS,S/AS01E at the start of the malaria transmis-
sion season [8]. Most breakthrough cases among children 
in the combined intervention group occurred during the 
last month of the malaria transmission season, and if 
these children had been given an additional fifth round of 
SMC, they would have been almost completely protected 
from clinical malaria. This trial is now being continued 
with an additional yearly pre-transmission season dose 
of RTS,S/AS01E, given with or without SMC, until chil-
dren reach the age of five years, the age after which SMC 
is no longer administered in Burkina Faso or Mali. A fifth 
round of SMC will be given in the study area in Burkina 
Faso in 2021 in concordance with a national strategy on 
the delivery of SMC in the country, which has one of the 
highest rates of malaria transmission in Africa. In Sen-
egal, SMC is given up to the age of 10 years and here, and 
in any similar situation, consideration could be given to 
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extending the age of seasonal vaccination beyond 5 years 
provided that it can be shown that many repeated doses 
of vaccine are safe and effective.
Combination of seasonal vaccination with an effec-
tive programme of chemoprevention could have a 
major impact on the malaria burden in the countries of 
the African Sahel and sub-Sahel where malaria trans-
mission is markedly seasonal, and where six of the ten 
African countries included in the WHO’s ‘High burden-
High Impact’ programme are located. However, further 
work is required to determine whether a programme of 
this kind could be deployed at scale and, if so, how this 
might be achieved most effectively. Potential approaches 
include utilization of targeted vaccination programmes 
to deliver both the priming and the booster doses with 
the latter given just prior to the malaria transmission sea-
son, as done during the first phase of the trial currently 
underway in Burkina Faso and Mali, utilizing the heath 
facilities and out reach clinics of the Expanded Pro-
gramme of Immunization (EPI) to give both priming and 
booster doses, as is being done in the pilot RTS,S/AS01E 
programmes currently underway in Ghana, Kenya and 
Malawi [9] or using a combination of the two approaches 
with the three priming doses being delivered through the 
EPI clinic based programme and and pre-transmission 
season booster doses given through a mass vaccination 
campaign. Which approach might be optimal in a specific 
area is likely to be influenced by the vaccination coverage 
currently achieved through the routine EPI programme 
in a particular area, the duration of the transmission sea-
son, and the age pattern of malaria (particularly severe 
malaria) in the target population. Repeated mass cam-
paigns would be demanding but might achieve higher 
coverage with the malaria vaccine than administration of 
priming and booster doses at routine EPI clinics or out-
reach clinics in some areas. The feasibility, acceptability 
to the local population and health service providers, and 
the economic costs of different approaches to delivering 
the combination of seasonal vaccination and SMC need 
to be explored.
Providing chemopreventive cover at the time 
of vaccination with an attenuated vaccine
Several studies have shown that providing chemopreven-
tive cover with chloroquine or pyrimethamine at the time 
of vaccination with the viable sporozoites PfSPZ (PfSPZ-
CVac) can induce with a very high level of protection 
against a challenge infection, even with a heterologous 
strain of parasite [10, 11]. Because PfSPZ-CVac uses via-
ble parasites, this approach to malaria vaccination may 
be more applicable to travellers and the military who can 
be kept under close observation after vaccination than 
to communities where close follow-up would be more 
challenging. In the case of some malaria vaccines, it may 
also be important to clear malaria parasites by adminis-
tration of a therapeutic dose of an effective anti-malarial 
prior to vaccination.
Additional opportunities for combining 
pre‑erythrocytic vaccination 
with chemoprevention
Based on the encouraging results obtained in the RTS,S/
AS01E plus SMC trial, it is important to consider whether 
there are other clinical or epidemiological situations in 
which combining vaccination with a pre-erythrocytic 
malaria vaccine and chemoprevention could prove a 
valuable malaria control tool. Some of the possible situ-
ations in which this might be the case are considered 
below.
Intermittent preventive treatment in infants
IPTi with sulfadoxine-pyrimethamine (IPTi-SP) was rec-
ommended by the WHO for use in countries with a high 
burden of malaria in infants and a low prevalence of SP 
resistance in 2010 [12]. Three or four administrations of 
IPTi-SP during the first year of life provided 30% pro-
tection against clinical attacks of malaria [13], although 
this pooled estimate did not include data from a rand-
omized clinical trial undertaken in northern Tanzania 
that showed no effect because it was conducted in an 
area with very high SP resistance [14]. To date, only one 
country (Sierra Leone) has adopted IPTi at the national 
level. However, in light of the faltering in progress in 
malaria control in a number of high burden countries in 
Africa, the potential of IPTi in countries where malaria 
transmission is perennial is currently being reconsidered. 
The efficacy of IPTi could be improved by increasing 
the number of times that the anti-malarial drug is given 
and/or by extending the period of drug administration 
beyond the first year of life (expanded IPTi) to cover the 
period when there is still a high risk of malaria, includ-
ing severe malaria, in many highly endemic countries. In 
addition, replacing SP with a more efficacious antimalar-
ial such as dihydroartemisinin-piperaquine (DHA-PPQ) 
could allow expansion of IPTi use to areas where IPTi 
cannot currently be deployed because of a high level of 
SP resistance.
The results of the RTS,S/AS01E  +  SMC trial sug-
gest that the combination of a pre-erythrocytic vaccine 
with chemoprevention given for the first 2  years of life 
(expanded IPTi plus vaccination) would provide much 
greater protection than IPTi or RTS,S/AS01E given alone, 
and this approach needs to be explored. In the RTS,S/
AS01E pilot study, RTS,S/AS01E is given at 5, 6, 7 and 
22 months of age in Malawi, and at 6, 7, 9 and 24 months 
of age in Ghana and Kenya through the EPI programme; 
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anti-malarials could be given at these time points, 
together with additional doses at 12, 15, and 18 months. 
Adoption of this approach would require evaluation of 
whether administration of anti-malarials at the same 
time as RTS,S/AS01E vaccination had any adverse effect 
on the immune response to the vaccine or IPTi efficacy 
and that this approach is safe, including an evaluation of 
the safety of the administration of multiple doses of SP 
during the first two years of life. However, it is reassuring 
that an early IPTi study showed that co-administration of 
SP with routine EPI vaccines had no adverse impact on 
their immunogencity [15], and thus an adverse impact on 
the immune response to a malaria vaccine is unlikely.
Intermittent preventive treatment in pregnancy
Intermittent preventive treatment in pregnancy with 
sulfadoxine-pyrimethamine (IPTp-SP) is one of the main-
stays for the prevention of malaria in pregnancy and 
is administered as three tablets on a single occasion at 
each scheduled ANC contact from the second trimes-
ter onwards, provided that these visits occur at least 
1  month apart. However, even when monthly doses are 
given under trial conditions, malaria infection of the pla-
centa may still occur [16], and coverage with monthly 
courses of IPTp-SP is frequently not optimal [1]. In addi-
tion, the efficacy of IPTp-SP is diminished in areas where 
a high level of resistance to SP is present [17]. DHA-PPQ 
is a potential alternative to SP for IPTp, although the use 
of this drug combination requires a three-day course for 
each dose and adherence to a monthly dosing schedule 
to provide full protection [18–20]. IPTp with DHA-PQ 
is superior to IPTp-SP in preventing malaria in pregnant 
women in some epidemiological situations but not in 
preventing low birth weight [21, 22].
A potential way of building on the protection provided 
by IPTp is to combine it with vaccination with either a 
vaccine directed specifically at prevention of infection 
of the placenta [23, 24] or with a pre-erythrocytic vac-
cine which would act in combination with the schizon-
tocidal activity of SP or DHA-PQ in a similar manner to 
that seen in the combination with the anti-malarial treat-
ments used for SMC. This approach might overcome the 
challenge of improving the anti-malarial protection of 
IPTp-SP. There is a natural hesitancy about administer-
ing a malaria vaccine during pregnancy, especially dur-
ing the first trimester, but the potential for protecting 
both mother and baby from the serious adverse effects of 
malarial infection by vaccination is now gaining increas-
ing consideration, [25] and a trial of the PfSPZ vaccine in 
pregnancy is now being planned. A potential approach 
could be to prime women of child-bearing age with the 
required number of doses of vaccine prior to their first 
pregnancy, in order to reduce the chance that they might 
be infected prior to their first attendance at an antena-
tal clinic and thus protected during the first trimester. 
Provided that the durability of protection provided by a 
malaria vaccine was sufficient, girls could receive their 
priming doses of malaria vaccine at the same time as 
they received human papiloma virus vaccine (HPV), now 
included in the routine immunization schedule of several 
African countries, although uptake of HPV vaccines is 
currently low in many malaria endemic countries. Uptake 
this might be enhanced by co-admininstration with a 
malaria vaccine. If this approach was to be followed, it 
would be necessary to show that there were no adverse 
interactions between the two vaccines. Priming would 
be followed by administration of a booster dose, together 
with the first dose of IPTp, at the first clinic attendance 
outside the first trimester of pregnancy. A single booster 
dose could then be given at the start of each subsequent 
pregnancy, if this proved to be necessary to sustain pro-
tective immunity. This approach would avoid a need to 
give multiple doses of malaria vaccine during pregnancy.
Post‑hospital discharge malaria chemoprevention
African children admitted to hospital with severe anae-
mia have a high mortality, or frequently require re-
admission to hospital during the first few months after 
their discharge [26]. In malaria-endemic areas, protect-
ing these children from further attacks of malaria during 
this period of heightened vulnerability is critical. Follow-
ing on from preliminary results of an initial, small study 
of post-discharge chemoprophylaxis with pyrimethamine 
plus dapsone  (Maloprim®) [27] and another trial with 
monthly SP given until the end of the rainy season in 
Gambian children who had been discharged from hospi-
tal after treatment for severe anaemia [28], a larger trial 
was undertaken in Malawi. This showed that this group 
of at-risk children could be protected for a period of 
3 months by providing them with two, monthly courses 
of treatment with artemether-lumefantrine (AL) after 
their discharge from hospital [29]. These findings have 
been confirmed recently in a large, placebo-controlled 
trial conducted in highly malarious areas in nine hospi-
tals in Uganda and western Kenya [30]. In this trial, three 
months of post-discharge malaria chemoprevention 
(PMC) with monthly DHA-PQ in children who had been 
admitted to hospital with severe anaemia resulted in a 
70% reduction in a combination of mortality or hospital 
readmission during the first three months after discharge 
from the hospital. However, this protective effect was not 
sustained, and children remained at high risk of dying or 
requiring readmissions after the protective level of pipe-
raquine levels had waned so that by six months after dis-
charge, the overall reduction in mortality and hospital 
readmission had fallen to 35% [30].
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The findings from these studies indicate that a period 
of protection longer than three months is required for 
this high-risk group of children following discharge from 
hospital, and this could potentially be achieved by com-
bining PMC with vaccination with a pre-erythrocytic 
vaccine such as RTS,S/AS01E. If a child had not previ-
ously received RTS,S/AS01E, three priming injections of 
malaria vaccine could be given during the period of pro-
tection provided by chemotherapy, after which the effi-
cacy provided by the vaccine would come into play. In 
the case of a child whose records showed that s/he had 
previously been primed with RTS,S/AS01E, a booster 
dose could be given shortly before discharge from the 
hospital. Children admitted to hospital for treatment of 
severe anaemia are still likely to have lower haemoglobin 
concentrations than normal, and it will be important to 
ascertain if this might adversely affect immune responses 
to the malaria vaccine.
Sickle cell disease
Children with sickle cell disease living in a malaria-
endemic area are at elevated risk of frequent hospitali-
zation, and clinical malaria is a common precipitating 
cause of a sickle cell crisis. Thus, it is recommended that 
children with sickle cell disease resident in malaria-
endemic areas should receive some form of chemopre-
vention. However, chemoprevention with an effective 
drug is currently provided infrequently to these children 
in many malaria-endemic areas [31]. Protection could 
be improved by chemoprevention with an effective anti-
malarial such as DHA-PPQ and this is being evaluated 
(Clinicaltrial.gov NCT03178643 and NCT04844099). 
The results of the RTS,S/AS01E  +  SMC trial suggest that 
an even higher level of protection could be achieved by 
combining an effective regimen of chemoprevention with 
RTS,S/AS01E vaccination. A similar approach might be 
adopted for other high-risk groups of children, such as 
those with severe malnutrition, provided that it could be 
shown that they could respond effectively to a specific 
vaccine.
The final stages of elimination
In the final stages of a national or regional elimination 
programme, all available malaria control tools may be 
needed, including an effective screening and treatment 
programme, vector control and mass drug administra-
tion (MDA) with an effective long-acting anti-malarial 
drug combination that includes a transmission-blocking 
component. The chances of success could be enhanced 
by combining the MDA with the administration of a pre-
erythrocytic malaria vaccine as is planned for the malaria 
elimination programme on the island of Bioko [32]. More 
than one round of MDA might be needed and inclusion 
of a transmission blocking vaccine would help to pre-
vent re-introduction of the infection if elimination was 
achieved successfully. A recent study conducted in adults 
in Thailand [33] that showed that combining administra-
tion of RTS,S/AS01E with DHA-PPQ and a single dose of 
primaquine had no adverse impact on either drug con-
centrations or the immune response to the vaccine pro-
vides important preliminary data on how vaccination 
and chemoprevention might be combined successfully 
in a malaria elimination programme. MDA is currently 
recommended in some situations other than elimination 
programmes such as emergencies and breakdowns in the 
health system, and potentially vaccination could be used 
to supplement MDA in these situations. This might be 
challenging at the height of an emergency, but could be 
a useful intervention in more settled refugee or internally 
displaced populations at high risk of malaria.
Conclusion
Malaria may, one day, be controlled effectively using a 
single intervention such as a highly effective, multi-stage 
vaccine or through a gene drive mosquito programme. 
Meanwhile, achieving effective malaria control in coun-
tries with a high level of transmission is likely to be 
achieved only through a combination of different inter-
ventions, the combination selected on the basis of the 
local epidemiological situation. In several of the situa-
tions considered in this review, and potentially in others 
in which subjects are exposed to a high risk of malaria, 
combining a pre-erythrocytic vaccine with chemopre-
vention could be a promising way forward but such pro-
grammes will need to be accompanied by monitoring for 
the potential emergence of drug resistance and of vaccine 
escape parasites.
This commentary has focussed on potential ways of 
harnessing a potential synergy between chemopreventive 
strategies and the immune response generated by vacci-
nation. The recent report of the success of an extended 
half-life monoclonal antibody in preventing malaria in 
challenged volunteers [34] provides another potential, 
exciting way in which the power of drugs and of the 
immune response could be used in synergy to enhance 
malaria control in many of the situations described in 
this paper.
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